In the claims:

Please amend the claims as follows:

1-15. (Cancelled).

16-42. (Withdrawn).

43. (Previously Amended) A method for reducing immune-mediated damage to cells, tissues or organs associated with graft versus host disease, the method comprising administering to a transplant patient an immunoprotective amount of a polypeptide consisting of the amino acid sequence of a polypeptide fragment of SEQ ID NO:6, the polypeptide fragment comprising the amino acid sequence AVLSAEQLR (SEQ ID NO:3).

44. (Previously Amended) A method for reducing immune-mediated damage to cells, tissues or organs associated with graft versus host disease, the method comprising administering to a transplant patient an immunoprotective amount of a polypeptide comprising the amino acid sequence of a polypeptide fragment of SEQ ID NO:6, the polypeptide fragment comprising the amino acid sequence AVLSAEQLR (SEQ ID NO:3)

45. (Previously Amended) A method for reducing immune-mediated damage to cells, tissues or organs associated with graft versus host disease, the method comprising administering to a transplant patient an immunoprotective amount of a polypeptide consisting essentially of the amino acid sequence of a polypeptide fragment of SEQ ID NO:6, the polypeptide fragment of SEQ ID NO:6 comprising the amino acid sequence AVLSAEQLR (SEQ ID NO:3).

46. (Previously Amended) A method for reducing immune-mediated damage to cells, tissues or organs associated with graft versus host disease, the method comprising administering to a transplant patient an immunoprotective amount of a polypeptide comprising the amino acid sequence AVLSAEQLR (SEQ ID NO:3).

47. (Previously Amended) A method for reducing immune-mediated damage to cells, tissues or organs associated with graft versus host disease, the method comprising administering to a transplant patient immunoprotective amount of a polypeptide consisting essentially of the amino acid sequence AVLSAEQLR (SEQ ID NO:3).

48-56. (Cancelled).

57. (Previously Amended) The method of any one of claims 43-47 further comprising administering to the transplant patient-a composition comprising brefeldin A.

58-59. (Cancelled)

60. (Previously Added) The method of any of claims 43-47 and 57 wherein the transplant patient is a bone marrow transplant patient.

61. (New) A method for reducing immune-mediated damage to cells, tissues or organs caused by CIK cells, the method comprising contacting a cell, tissue or organ with an immunoprotective amount of a polypeptide consisting of the amino acid sequence of a polypeptide fragment of SEQ ID NO:6, the polypeptide fragment comprising the amino acid sequence AVLSAEQLR (SEQ ID NO:3).

62. (New) A method for reducing immune-mediated damage to cells, tissues or organs caused by CIK cells, the method comprising contacting a cell, tissue or organ with an immunoprotective amount of a polypeptide comprising the amino acid sequence of a polypeptide fragment of SEQ ID NO:6, the polypeptide fragment comprising the amino acid sequence AVLSAEQLR (SEQ ID NO:3)

63. (New) A method for reducing immune-mediated damage to cells, tissues or organs caused by CIK cells, the method comprising contacting a cell, tissue or organ with an immunoprotective amount of a polypeptide consisting essentially of the amino acid sequence of

a polypeptide fragment of SEQ ID NO:6, the polypeptide fragment of SEQ ID NO:6 comprising the amino acid sequence AVLSAEQLR (SEQ ID NO:3).

64. (New) A method for reducing immune-mediated damage to cells, tissues or organs caused by CIK cells, the method comprising contacting a cell, tissue or organ with an immunoprotective amount of a polypeptide comprising the amino acid sequence AVLSAEQLR (SEQ ID NO:3)

65. (New) A method for reducing immune-mediated damage to cells, tissues or organs caused by CIK cells, the method comprising contacting a cell, tissue or organ with an immunoprotective amount of a polypeptide consisting essentially of the amino acid sequence AVLSAEQLR (SEQ ID NO:3).

66. (New) The method of any one of claims 61-65 wherein the contacting takes place *in vitro*.

67. (New) The method of any one of claims 61-65 wherein the contacting takes place *in vivo*.